The therapy of melanoma changed radically with the identification of recurrent mutations in genes coding for members of the MAPK pathway, which then led to the design of targeted inhibitors for both BRAF and MEK tyrosine kinases. The gene discussed is MAP2K7; the disease is melanoma.